Dextromethorphan

Generic Name: Dextromethorphan

Brand Names: Auvelity, Benylin DM, Bromfed DM, Broncotron, Cepacol Sore Throat Plus Cough, Cheracol D, Children's Nyquil Cold and Cough, Chloraseptic Sore Throat + Cough, Coricidin Hbp Chest Congestion, Coricidin Hbp Cough and Cold, Creomulsion, DM, Dayquil Cough, Delsym, Delsym Cough Plus Chest Congestion DM, Delsym Cough Plus Soothing Action, Delsym Cough Relief Plus Soothing Action, Despec Reformulated Jun 2008, Diabetic Tussin DM, Dimetapp Long Acting Cough Plus Cold, Diphen, G-zyncof, Mucinex Children's Cough, Mucinex Cough, Mucinex DM, Nuedexta, Nyquil Cough, Pediacare Children's Cough and Congestion, Promethazine DM, Robafen Cough, Robafen DM, Robitussin 12 Hour Cough Relief, Robitussin Cough & Congestion, Robitussin Maximum Strength Cough Plus Chest Congestion DM, Robitussin Nighttime Cough DM, Robitussin Pediatric Cough & Cold LA, Robitussin Pediatric Cough Suppressant, Safetussin DM, Safetussin PM, Scot-tussin DM, Scot-tussin Diabetic CF, Scot-tussin Sugar Free DM, Sudafed PE Children's Cold & Cough, Triaminic Day Time Cold & Cough, Tusnel Diabetic

Drug Type: Small Molecule

Chemical Formula: C_₁₈H_₂₅NO

CAS Number: 125-71-3

Unique Ingredient Identifier: 7355X3ROTS

Background: Dextromethorphan is a levorphanol derivative and codeine analog commonly used as a cough suppressant and also a drug of abuse. Although similar in structure to other opioids, it has minimal interaction with opioid receptors.

Dextromethorphan was granted FDA approval before 3 December 1957.

Indication: Dextromethorphan is indicated in combination with brompheniramine and pseudoephedrine in the treatment of coughs and upper respiratory symptoms associated with allergies or the common cold. Dextromethorphan is also used in combination with guaifenesin as an over-the-counter product to relieve a cough. Dextromethorphan in combination with quinidine is indicated in the treatment of pseudobulbar affect.

Associated Conditions: Allergic cough, Common Cold, Cough, Cough caused by Common Cold, Coughing caused by Allergies, Coughing caused by Bronchitis, Coughing caused by Flu caused by Influenza, Fever, Flu caused by Influenza, Headache, Irritative cough, Itching of the nose, Itching of the throat, Major Depressive Disorder (MDD), Nasal Congestion, Pseudobulbar Affect (PBA), Rhinorrhoea, Sneezing, Cold or flu syndrome, Upper respiratory symptoms, Watery itchy eyes

Associated Therapies: Airway secretion clearance therapy, Bronchodilation, Oropharyngeal antisepsis

Clinical Trials

Acute Cough Study In Children

Phase 4

Terminated

Conditions: Common Cold
Infections, Upper Respiratory Tract

Interventions: Drug: Dextromethorphan
Drug: Placebo

First Posted Date: 2010-12-09

Last Posted Date: 2012-09-20

Lead Sponsor: Pfizer

Target Recruit Count: 140

Registration Number: NCT01257542

Locations: 🇺🇸
DMI Research, Pinellas, Florida, United States
🇺🇸
Cyn3rgy Research, Gresham, Oregon, United States
🇺🇸
Clinical Research Associates Incorporated, Nashville, Tennessee, United States

and more 1 locations

Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097 in Treating Patients With Advanced Solid Tumors

Phase 1

Completed

Conditions: Adult Solid Neoplasm

Interventions: Drug: Gamma-Secretase Inhibitor RO4929097
Drug: Ketoconazole
Drug: Rifampin
Drug: Midazolam Hydrochloride
Drug: Omeprazole
Drug: Tolbutamide
Drug: Dextromethorphan Hydrobromide
Other: Pharmacological Study
Other: Laboratory Biomarker Analysis

First Posted Date: 2010-10-11

Last Posted Date: 2014-12-23

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 17

Registration Number: NCT01218620

Locations: 🇺🇸
University of Wisconsin Hospital and Clinics, Madison, Wisconsin, United States

Add-On Therapy to Risperidonein Schizophrenia

Phase 2

Completed

Conditions: Schizophrenia

Interventions: Drug: Dextromethorphan

First Posted Date: 2010-08-26

Last Posted Date: 2013-02-28

Lead Sponsor: National Cheng-Kung University Hospital

Target Recruit Count: 161

Registration Number: NCT01189006

Locations: 🇨🇳
Ru-Band Lu, Tainan, Taiwan

Combined Therapy of Methadone and Dextromethrophan

Phase 3

Conditions: Opioid Abuse

Interventions: Drug: Dextromethorphan

First Posted Date: 2010-08-26

Last Posted Date: 2010-08-26

Lead Sponsor: National Cheng-Kung University Hospital

Target Recruit Count: 1500

Registration Number: NCT01189097

Locations: 🇨🇳
Ru-Band Lu, Tainan, Taiwan

Add-on Dextromethorphan in Bipolar Disorders

Phase 3

Completed

Conditions: Bipolar Disorder

Interventions: Drug: Valproate
Drug: Dextromethorphan 30 mg
Drug: Dextromethorphan 60 mg per day
Drug: Placebo

First Posted Date: 2010-08-25

Last Posted Date: 2013-09-17

Lead Sponsor: National Cheng-Kung University Hospital

Target Recruit Count: 300

Registration Number: NCT01188265

Locations: 🇨🇳
Ru-Band Lu, Tainan, Taiwan

Erythrocytes-Mediated Delivery Of Dexamethasone 21-Phosphate In Steroid-Dependent Ulcerative Colitis

Phase 2

Conditions: Ulcerative Colitis

Interventions: Drug: Dex 21-P
Drug: Placebo

First Posted Date: 2010-07-29

Last Posted Date: 2011-06-28

Lead Sponsor: Casa Sollievo della Sofferenza IRCCS

Target Recruit Count: 40

Registration Number: NCT01171807

Locations: 🇮🇹
Casa Sollievo della Sofferenza Hospital, San Giovanni Rotondo, Italy

Dextromethorphan and Silymarin in Chronic Kidney Disease (CKD) Patients

Phase 3

Conditions: Proteinuria

Interventions: Drug: Silymarin
Drug: sugar pill
Drug: Dextromethorphan

First Posted Date: 2010-03-24

Last Posted Date: 2010-03-24

Lead Sponsor: National Cheng-Kung University Hospital

Target Recruit Count: 45

Registration Number: NCT01091324

Locations: 🇨🇳
National Cheng-Kung University Hospital, Taian, Taiwan

A Drug-Drug Interaction Study of Abiraterone Acetate Plus Prednisone With Dextromethorphan and Theophylline in Patients With Metastatic Castration-Resistant Prostate Cancer

Phase 1

Completed

Conditions: Prostate Neoplasms

Interventions: Drug: Abiraterone acetate
Drug: Prednisone
Drug: Theophylline
Drug: Dextromethorphan hydrobromide

First Posted Date: 2009-11-23

Last Posted Date: 2013-04-12

Lead Sponsor: Janssen Research & Development, LLC

Target Recruit Count: 34

Registration Number: NCT01017939

Locations: 🇺🇸
START - South Texas Accelerated Research Therapeutics, LLC, San Antonio, Texas, United States
🇺🇸
Tower Cancer Research Foundation, Beverly Hills, California, United States
🇨🇦
BC Cancer Agency, Vancouver, British Columbia, Canada